Last reviewed · How we verify
GP40071
GP40071 is a small molecule drug that targets the renin-angiotensin system.
GP40071 is a small molecule drug that targets the renin-angiotensin system. Used for Hypertension, Heart failure.
At a glance
| Generic name | GP40071 |
|---|---|
| Also known as | Insulin aspart |
| Sponsor | Geropharm |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
GP40071 works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in regulating blood pressure. This leads to a decrease in angiotensin II levels, resulting in vasodilation and a reduction in blood pressure. Additionally, GP40071 may also have a protective effect on the kidneys by reducing proteinuria and slowing the progression of kidney disease.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Headache
- Fatigue
- Nausea
Key clinical trials
- Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP40071 CI brief — competitive landscape report
- GP40071 updates RSS · CI watch RSS
- Geropharm portfolio CI